^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TNN (Tenascin N)

    i
    Other names: TNN, Tenascin N, TNW, Tenascin-W, Tenascin-N, TN-W, TN-N, Tenascin W
    Associations

    News

    Trials
    13d
    Non-small cell lung carcinomas with diffuse co-expression of TTF-1 and p40: Clinical, pathological and molecular characterization of a tumor subtype. (PubMed, Virchows Arch)
    Notably, SYNE1, TMEM132C, and TNN were identified as characteristic mutations, defining a distinct mutational profile that sets this rare subtype apart from both SCC and ADC. Our findings highlight that NSCLC with diffuse co-expression of TTF-1 and p40 probably constitutes a distinct clinicopathological subtype with rapid clinical progression and poor prognosis, defined by unique morphological characteristics, a biphenotypic immunoprofile, and specific molecular alterations.
    Journal
    |
    TTF1 (Transcription Termination Factor 1) • NKX2-1 (NK2 Homeobox 1) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1) • TNN (Tenascin N)
    2ms
    Bioinformatics-based multi-omics and machine learning analysis identifies stemness-associated molecular subtypes and a prognostic index in breast cancer. (PubMed, Transl Cancer Res)
    This study classified BC by mRNAsi-related genes and established corresponding risk models. The findings of the present study propose a novel classification tool based on stem cell characteristics, which has the potential to be employed for prognostic stratification in BC patients and to offer guidance for developing personalised treatment strategies.
    Journal • Tumor mutational burden • BRCA Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • BRCA (Breast cancer early onset) • PRDX1 (Peroxiredoxin 1) • CD24 (CD24 Molecule) • PDLIM4 (PDZ and LIM domain 4) • PGK1 (Phosphoglycerate Kinase 1) • TNN (Tenascin N)
    6ms
    Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis. (PubMed, Br J Cancer)
    Advanced LUAD tumours exhibit higher copy-number alteration burden, with distinct alterations associated with tumour progression and metastasis. CDKN2A homozygous deletions predict poor prognosis in early disease, while KRAS mutant allele-specific imbalance is enriched in advanced tumours.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • EPHA3 (EPH receptor A3) • PAX8 (Paired box 8) • TNN (Tenascin N)
    |
    KRAS mutation • CDKN2A deletion
    7ms
    Somatic Mutations Profiling in Genes Other than BRCA and TP53 Increasing Breast Carcinoma Risk Among Pakistani Patients. (PubMed, Rev Recent Clin Trials)
    This study unveils new somatic alterations in different genes among early-onset Pakistani breast cancer patients, offering valuable insights for drug design targeting breast carcinoma.
    Journal • BRCA Biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • ARID1A (AT-rich interaction domain 1A) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • KMT2C (Lysine Methyltransferase 2C) • BRCA (Breast cancer early onset) • CDH1 (Cadherin 1) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • KHDRBS1 (KH RNA Binding Domain Containing, Signal Transduction Associated 1) • GATA3 (GATA binding protein 3) • DNAH8 (Dynein Axonemal Heavy Chain 8) • LAMA3 (Laminin Subunit Alpha 3) • TNN (Tenascin N) • CDC27 (Cell Division Cycle 27)
    |
    TP53 mutation • BRCA mutation
    11ms
    Analysis of hydrogen sulfide-related signatures of breast cancer identified 2 distinct subtypes: Implications for individualized therapeutics. (PubMed, Medicine (Baltimore))
    Our findings highlight the clinical relevance of HSRGs in BC, providing a basis for precise molecular classification and prognosis evaluation. The developed risk feature and nomogram offer practical tools for guiding personalized treatment strategies in clinical practice.
    Journal • IO biomarker
    |
    TNN (Tenascin N)
    1year
    Genomic Signatures of Recurrence After Resection of Early-Stage Node-Negative Colon Cancer. (PubMed, Ann Surg Oncol)
    This study identified novel genomic signatures that may improve risk stratification in early-stage node-negative CC, potentially guiding the selection of high-risk patients for adjuvant therapy.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A) • COL6A1 (Collagen Type VI Alpha 1 Chain) • COL6A3 (Collagen Type VI Alpha 3 Chain) • BCL9 (BCL9 Transcription Coactivator) • NALCN (Sodium Leak Channel, Non-Selective) • TNN (Tenascin N)
    |
    KRAS mutation
    1year
    Clinical value of multi-slice spiral CT in evaluating preoperative TNN staging and postoperative recurrence and metastasis of colon carcinoma. (PubMed, SLAS Technol)
    The diagnosis of recurrent TNM stage was consistent (Kappa=0.893, 0.801, 1.000) Multi-slice spiral CT is of high diagnostic coincidence rate, high accuracy of TNM staging and rapid noninvasive examination. It can obtain reliable results in preoperative staging and postoperative recurrence and metastasis diagnosis, which is worth popularizing in clinic.
    Journal
    |
    TNN (Tenascin N)
    over1year
    Screening differentially expressed proteins to distinguish thymoma (B1 and B3) from thymic cysts based on tandem mass tag (TMT) technology. (PubMed, J Cardiothorac Surg)
    GEPIA validated that LGALS3BP was significantly upregulated in thymoma patients. In conclusion, LGALS3BP might be an essential biomarker to identify thymoma from the thymic cyst.
    Journal
    |
    LGALS3 (Galectin 3) • LGALS3BP (Lectin galactoside-binding soluble 3-binding protein) • TNN (Tenascin N)
    almost2years
    Cancer-associated fibroblast-derived gene signature discriminates distinct prognoses by integrated single-cell and bulk RNA-seq analyses in breast cancer. (PubMed, Aging (Albany NY))
    Integrating single-cell and bulk RNA-seq analyses, we identified a list of compositive CAF-associated biomarkers and developed a novel CAF-related prognostic model for breast cancer. This robust CAF-derived gene signature acts as an excellent predictor of patient outcomes and treatment responses in breast cancer.
    Journal • Tumor mutational burden • Gene Signature
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • SDC1 (Syndecan 1) • PDLIM4 (PDZ and LIM domain 4) • TNN (Tenascin N)
    almost2years
    Trained neural networking framework based skin cancer diagnosis and categorization using grey wolf optimization. (PubMed, Sci Rep)
    The threshold value validation of the dimensional mapping datasets is effectively optimized and trained under the neural networking framework further expanded via federated learning standards. The technique has demonstrated 95.82% accuracy under GWO technique and 94.9% on inter-combination of Trained Neural Networking (TNN) framework and Recessive Learning (RL) in accuracy.
    Journal
    |
    TNN (Tenascin N)
    2years
    Identification and validation of a new prognostic signature based on cancer-associated fibroblast-driven genes in breast cancer. (PubMed, World J Clin Cases)
    We introduced a newly-discovered CAFs-associated gene signature, which can be employed to estimate BC patient outcomes conveniently and accurately.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IL18 (Interleukin 18) • TNN (Tenascin N)
    2years
    Analysis of Somatic Mutations in the TCGA-LIHC Whole Exome Sequence to Identify the Neoantigen for Immunotherapy in Hepatocellular Carcinoma. (PubMed, Curr Issues Mol Biol)
    These genes are recognized to be immune targets. In the future, immune checkpoint inhibitors may be developed to prolong patient survival times and prevent hepatocellular carcinoma (HCC) through immunotherapy.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MUC16 (Mucin 16, Cell Surface Associated) • MUC4 (Mucin 4, Cell Surface Associated) • APOB (Apolipoprotein B) • ABCA1 (ATP Binding Cassette Subfamily A Member 1) • PCLO (Piccolo Presynaptic Cytomatrix Protein) • TNN (Tenascin N) • ABCA13 (ATP Binding Cassette Subfamily A Member 13)
    |
    TP53 mutation